Subgroup analysis revealed that SQLE consistently predicted worse outcomes for both DFS (4 studies; HR = 2.51, 95% CI: 1.64–3.86, I2 = 67%) and RFS in colorectal cancer (2 studies; HR = 4.04, 95% CI: 3.01–5.42, I2 = 0%), while SREBP-1 showed significant association with worse DFS (2 studies; HR = 2.33, 95% CI: 1.36–3.97, I2 = 0%). This evidence concerns the gene SREBF1 and colorectal cancer.